ClinicalTrials.Veeva

Menu

Post-COVID-19 Monitoring in Routine Health Insurance Data (POINTED)

T

Technische Universität Dresden

Status

Completed

Conditions

Virus Diseases
Epidemiology

Treatments

Other: Exposed to a SARS-CoV-2 infection

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05074953
POINTED

Details and patient eligibility

About

The SARS-CoV-2 infection was in 2020 responsible for new disease related chronic conditions which have been referred to as Post-COVID. To date it is still unknown how common this condition is and which symptoms are related to it. The aim of the study is to monitor the onset of these conditions in a large observational study consisting of German health insurance data.

Full description

SARS-CoV-2 is a virus of the coronavirus family, which includes a large number of viruses that can cause a wide variety of diseases in humans. The SARS-CoV-2 virus causes acute symptoms associated with the infection and can cause chronic conditions known as Post-COVID. To understand the prevalence and variety of Post-COVID a large observational study of health insurance data from Germany was set up. The exposed patients were identified by a diagnosis indicating a confirmed laboratory test for COVID.

The basic question concerns the burden of the Post-COVID condition. The study investigate which symptoms are more common in humans after the exposure to the virus compared to a matched unexposed cohort. Further will this be investigated in the subgroup of children and adolescents and those who have been hospitalized due to the virus infection.

Enrollment

157,134 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • At least one outpatient or inpatient diagnosis of COVID-19 with laboratory detection of the virus (ICD-10: U07.1!)
  • Continuously insured with the respective health insurance between 2019-01-01/birth and 2020-12-31/death

Exclusion criteria

Trial design

157,134 participants in 2 patient groups

Adults
Description:
145184 patients with COVID-19 over 17 years of age.
Treatment:
Other: Exposed to a SARS-CoV-2 infection
Children and adolescents
Description:
11950 patients with COVID-19 under 18 years of age.
Treatment:
Other: Exposed to a SARS-CoV-2 infection

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems